Technology Platform
Novel Proprietary N-Tab™ Platform for Developing Oral Peptide Therapies in Tablet Form
Oral Peptide Delivery Challenge
Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections. In chronic diseases where patients require persistent management, these cumbersome, often painful and high-priced injections can create a major treatment gap.
From a technical standpoint, oral delivery of therapeutic proteins is challenging due to the enzymatic degradation within the gastrointestinal tract and poor absorption into the blood stream due to the proteins’ polarity and molecular weight.
Our Solution
N-Tab™ Entera’s Proprietary Platform is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream
Unlocking Value with the N-Tab™ Platform:
✓ Preferred by Patients
Oral meds are easier to take and more convenient in chronic conditions
✓ Daily Tablet Unlocks Access to New Drug Classes
Tablet format makes new therapies possible
✓ Platform Designed to Address This Unmet Need
Built to overcome the key barriers to oral biologics – stability, absorption, and bioavailability
